Фенотипическое разнообразие макрофагов при раке яичников

55. Reinartz S., Finkernagel F., Adhikary T., Rohnalter V., Schumann T., Schober Y., Nock- her W.A., Nist A., Stiewe T., Jansen J.M., Wagner U., Muller-Brusselbach S., Muller R. A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome // Genome Biology and Evolution. 2016. № 17. A. 108. doi: 10.1186/s13059-016-0956-6

56. Schutyser E., Struyf S., Proost P., Opdenakker G., Laureys G., Verhasselt B., Peperstraete L., Van de Putte I., Saccani A., Allavena P., Mantovani A., Damme J.V. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma // The Journal of Biological Chemistry. 2002. Vol. 277, № 27. PP. 24584-24593. doi: 10.1074/jbc.M112275200

57. Korbecki J., Olbromski M., Dzi^giel P. CCL18 in the Progression of Cancer // The International Journal of Molecular Sciences. 2020. Vol. 21, № 21. A. 7955. doi: 10.3390/ijms21217955

58. Lane D., Matte I., Laplante C., Garde-Granger P., Carignan A., Bessette P., Rancourt C., Piche A. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling // Molecular Cancer. 2016. № 15. A. 58. doi: 10.1186/s12943- 016-0542-2

59. Montalban del Barrio I., Penski C., Schlahsa L., Stein R.G., Diessner J., Wцckel A., Dietl J., Lutz M.B., Mittelbronn M., Wischhusen J., Hausler S.F.M. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape // Journal for ImmunoTherapy of Cancer. 2016. Vol. 4, № 1. A. 49. doi: 10.1186/s40425-016-0154-9

References

1. Bray F, Ferlay J, Soeijomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492

2. Zlokachestvennye novoobrazovaniya v Rossii v 2020 godu (Zabolevaemost' i smertnost') [Malignant neoplasms in Russia in 2020 (morbidity and mortality)]. Kaprin AD, Starinskiy VV and Shakhzadova AO, editors. Moscow: MNIOI im. P.A.Gertsena - filial FGBU «NMITs radiologii» Minzdrava Rossii; 2021. 252 p. In Russian

3. Efimova O, Safonova M. Epidemiology of ovarian cancer in early stages. Acta Medica Eurasica. 2018;4:9-18. In Russian, English Summary

4. Spiridonova NV, Demura AA, Shchukin VYu. Otsenka soputstvuyushchey ginekologicheskoy patologii v gruppe patsientok reproduktivnogo vozrasta s opukholyami i opukholevidnymi obrazovaniyami yaichnikov [Evaluation of concomitant gynecological pathology in the group of patients of reproductive age with tumors and tumor-like formations of the ovaries]. MeditsinskiyAlfavit. 2020;16:10-14. In Russian

5. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;30(11):287-299. doi: 10.2147/IJWH.S197604

6. Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 2016;13(4):255-61. doi: 10.1038/nrclinonc.2015.224

7. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016; 2:16061 doi: 10.1038/nrdp.2016.61

8. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084

9. Baci D, Bosi A, Gallazzi M, et al. The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: a focus on innate immunity cells as therapeutic effectors. Int JMol Sci. 2020;21(9):3125. doi: 10.3390/ijms21093125

10. Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(6):595-606. doi: 10.1001/jama.2017.21421

11. Osborn G, Stavraka C, Adams R, et al. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clin Exp Immunol. 2021;uxab020. doi: 10.1093/cei/uxab020

12. Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V, Choinzonov E, Kzhyshkowska J. Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers. Front Oncol. 2020;10:566511. doi: 10.3389/fonc.2020.566511

13. Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoe- lomic metastasis of ovarian cancer. J Clin Invest. 2016;126(11):4157-4173. doi: 10.1172/JCI87252

14. Montfort A, Owen S, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, Bцhm S, Phar- oah P, McDermott J, Balkwill FR, Brenton JD. Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. Br J Cancer. 2020;122(12):1803-1810. doi: 10.1038/s41416-020-0822-x

15. Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, Di W. A high M1/M2 ratio of tumor- associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:19. doi: 10.1186/1757-2215-7-19

16. Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W, Ma X. Prognostic significance of tumor- associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017;147(1):181-187. doi: 10.1016/j.ygyno.2017.07.007

17. Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J, Liu J. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2012;12(3):259-67. doi: 10.7785/tcrt.2012.500312

18. Maccio A, Gramignano G, Cherchi MC, Tanca L, Melis L, Madeddu C. Role of M1- polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. Sci Rep. 2020;10(1):6096. doi: 10.1038/s41598-020-63276-1

19. Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, Madore J, Delvoye N, Mes-Masson AM, Provencher DM, Cailhier JF. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS One. 2012;7(6):e38541. doi: 10.1371/journal.pone.0038541

20. Qu QX, Huang Q, Shen Y, Zhu YB, Zhang XG. The increase of circulating PD-L1- expressing CD68(+) macrophage in ovarian cancer. Tumour Biol. 2016;37(4):5031-7. doi: 10.1007/s13277-015-4066-y

21. He YF, Zhang MY, Wu X, Sun XJ, Xu T, He QZ, Di W. High MUC2 expression in ovar

ian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoSOne.2013;8(12):e79769. doi:

10.1371/journal.pone.0079769

22. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203(4):871-81. doi: 10.1084/jem.20050930

23. Cortes M, Sanchez-Moral L, Barrios O, Fernandez-Acenero M, Martinez-Campanario MC, Esteve-Codia A, Darling DS, Gyorffy B, Lawrence T, Dean DC, Postigo A. Tumor- associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles. The EMBO Journal. 2017;36:3336-3355. doi: 10.15252/embj.201797345

24. Zhang W, Tian J, Hao Q. HMGB1 combining with tumor-associated macrophages enhanced lymphangiogenesis in human epithelial ovarian cancer. Tumour Biol. 2014 Mar;35(3):2175-86. doi: 10.1007/s13277-013-1288-8

25. Liu L, Wang X, Li X, Wu X, Tang M, Wang X. Upregulation of IGF1 by tumor- associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells. Oncol Rep. 2018;39(2):818-826. doi: 10.3892/or.2017.6148

26. Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):444-56. doi: 10.1152/ajpcell.00188.2015

27. Huang LL, Xia HH, Zhu SL. Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites. J Clin Transl Hepatol. 2014;2(1):58-64. doi: 10.14218/JCTH.2013.00010

28. Villert AB, Kolomiets LA, Yunusova NV, Ivanova AA. Ascites as a subject of studies in ovarian cancer. Siberian journal of oncology. 2019; 18( 1): 116-123. doi: 10.21294/18144861-2019-18-1-116-123 In Russian

29. Feki A, Berardi P, Bellingan G, Major A, Krause KH, Petignat P, Zehra R, Pervaiz S, Irminger-Finger I. Dissemination of intraperitoneal ovarian cancer: Discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. Critical Reviews in Oncology/Hematology. 2009;72(1):1-9. doi: 10.1016/j.critrevonc.2008.12.003

30. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nature Reviews. Cancer. 2013;13(4):273-82. doi: 10.1038/nrc3432

31. Gilmore AP. Anoikis. Cell Death and Differentiation. 2005;12 Suppl 2:1473-7. doi: 10.1038/sj.cdd.4401723

32. Steitz AM, Steffes A, Finkernagel F, Unger A, Sommerfeld L, Jansen JM, Wagner U, Graumann J, Mьller R, Reinartz S. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death and Disease. 2020;11(4):249. doi: 10.1038/s41419-020-2438-8

33. Motohara T, Masuda K, Morotti M, Zheng Y, El-Sahhar S, Chong KY, Wietek N, Alsaadi A, Karaminejadranjbar M, Hu Z, Artibani M, Gonzalez LS, Katabuchi H, Saya H, Ahmed AA. An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene. 2019;38(16):2885-2898. doi: 10.1038/s41388-018-0637-x

34. Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernandez VM, Pothuri B, Coleman RL. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. The Journal of Experimental Medicine. 2019;216(3):688-703. doi: 10.1084/jem.20180765

35. Winter SJ, Miller HA, Steinbach-Rankins JM. Multicellular Ovarian Cancer Model for Evaluation of Nanovector Delivery in Ascites and Metastatic Environments. Pharmaceutics. 2021;13(11): 1891. doi: 10.3390/pharmaceutics13111891

36. Capellero S, Erriquez J, Battistini C, Porporato R, Scotto G, Borella F, Di Renzo MF, Valabrega G, Olivero M. Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. International Journal of Molecular Sciences. 2022;23(2):833. doi: 10.3390/ijms23020833

37. Wang J, Liu C, Chang X, Qi Y, Zhu Z, Yang X. Fibrosis of mesothelial cell-induced peritoneal implantation of ovarian cancer cells. Cancer Management and Research. 2018;10:6641-6647. doi: 10.2147/CMAR.S183043

38. Kim S, Kim S, Kim J, Kim B, Kim SI, Kim M, Kwon S, Song YS. Evaluating tumor evolution via genomic profiling of individual tumor spheroids in a malignant ascites. Scientific Reports. 2018;8:12724. doi: 10.1038/s41598-018-31097-y

39. Uruski P, Mikula-Pietrasik J, Pakula M, Budkiewicz S, Drzewiecki M, Gaiday AN, Wier-

zowiecka M, Naumowicz E, Moszynski R, Tykarski A, Ksiqzek K. Malignant Ascites Promote Adhesion of Ovarian Cancer Cells to Peritoneal Mesothelium and Fibroblasts. International Journal of Molecular Sciences.2021;22(8):4222. doi:

10.3390/ijms22084222

40. Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, Mьller R. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Frontiers in Oncology. 2017;7:24. doi: 10.3389/fonc.2017.00024

41. Adhikary T, Wortmann A, Finkernagel F, Lieber S, Nist A, Stiewe T, Wagner U, MьllerBrьsselbach S, Reinartz S, Mьller R. Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics. 2017;18(1):243. doi: 10.1186/s12864-017-3630-9

42. Maccio A, Gramignano G, Cherchi MC, Tanca L, Melis L, Madeddu C. Role of M1- polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. Scientific Reports. 2020;10(1):6096. doi: 10.1038/s41598-020-63276-1

43. Worzfeld T, Finkernagel F, Reinartz S, Konzer A, Adhikary T, Nist A, Stiewe T, Wagner U, Looso M, Graumann J, Mьller R. Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment. Molecular & Cellular Proteomics. 2018;17(2):270-289. doi: 10.1074/mcp.RA117.000400

44. Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su MJ, Shah P, Iwanicki M, Walker SR, Kanodia A, Melms JC, Mei S, Lin JR, Porter CBM, Slyper M, Waldman J, Jerby-Arnon L, Ashenberg O, Brinker TJ, Mills C, Rogava M, Vigneau S, Sorger PK, Garraway LA, Konstantinopoulos PA, Liu JF, Matulonis U, Johnson BE, Rozenblatt- Rosen O, Rotem A, Regev A. A single-cell landscape of high-grade serous ovarian cancer. Nature Medicine. 2020;26(8):1271-1279. doi: 10.1038/s41591-020-0926-0

45. Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H, Takeya M. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Science. 2010;101(10):2128- 36. doi: 10.1111/j.1349-7006.2010.01652.x

46. Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. The International Journal of Clinical Oncology. 2013;18(1):1-9. doi: 10.1007/s10147-012-0396-6

47. Yin M, Shen J, Yu S, Fei J, Zhu X, Zhao J, Zhai L, Sadhukhan A, Zhou J. Tumor- Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis. OncoTargets and Therapy. 2019;12:8687-8699. doi: 10.2147/OTT.S216355

48. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Molecular Oncology. 2018;12(1):3-20. doi: 10.1002/1878-0261.12155

49. Long L, Hu Y, Long T, Lu X, Tuo Y, Li Y, Ke Z. Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoe- lomic metastasis of ovarian cancer. The Journal for ImmunoTherapy of Cancer. 2021;9(12):e003973. doi: 10.1136/jitc-2021-003973

50. Larionova I, Kazakova E, Gerashchenko T, Kzhyshkowska J. New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis. Cancers (Basel). 2021;13(13):3253. doi: 10.3390/cancers13133253

51. Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O, Wu L. Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer. Cancer Research. 2015;75(22):4742-52. doi: 10.1158/0008-5472.CAN-14-3373

52. Yin M, Zhou HJ, Zhang J, Lin C, Li H, Li X, Li Y, Zhang H, Breckenridge DG, Ji W, Min W. ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis. Journal of Clinical Investigation insight. 2017;2(18):e91828. doi: 10.1172/jci. insight. 91828

53. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Cata- la L, Ifrah N, Descamps P, Gamelin E, Gascan H, Hebbar M, Jeannin P. Tumor- associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor- associated macrophage-like cells. Blood. 2007;110(13):4319-30. doi: 10.1182/blood- 2007-02-072587

54. Reinartz S, Finkernagel F, Adhikary T, Rohnalter V, Schumann T, Schober Y, Nockher WA, Nist A, Stiewe T, Jansen JM, Wagner U, Mьller-Brьsselbach S, Mьller R. A tran- scriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biology and Evolution. 2016;17(1): 108. doi: 10.1186/s13059-016-0956-6

55. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. The Journal of Biological Chemistry. 2002;277(27):24584-93. doi: 10.1074/jbc.M112275200

56. Korbecki J, Olbromski M, Dziqgiel P. CCL18 in the Progression of Cancer. The International Journal of Molecular Sciences. 2020;21(21):7955. doi: 10.3390/ijms21217955

57. Lane D, Matte I, Laplante C, Garde-Granger P, Carignan A, Bessette P, Rancourt C, Piche A. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Molecular Cancer. 2016;15(1):58. doi: 10.1186/s12943-016- 0542-2

58. Montalban Del Barrio I, Penski C, Schlahsa L, Stein RG, Diessner J, Wцckel A, Dietl J, Lutz MB, Mittelbronn M, Wischhusen J, Hдusler SFM. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. Journal for ImmunoTherapy of Cancer. 2016;4:49. doi: 10.1186/s40425-016-0154-9

59. Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, Franco W, Scarcelli G, Polacheck WJ, Roque DM, Del Carmen MG, Huang HC, Demirci U, Rizvi I. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers (Basel). 2021;13(17):4318. doi: 10.3390/cancers13174318

Размещено на Allbest.ru